Life sciences start-up support powered by NGI
Starting up a company is tricky in any sector. It is particularly tough in one that is as fast moving as life sciences. The Netherlands Genomics Initiative fully recognises this difficulty and has put together a coherent support programme for life sciences starters by initiating a series of activities and partnering with existing start-up programmes.
Find out how we can help you!
LifeSciences@work brings start-up support activities, former- and future participants and experts community together. The support programme covers aspects such as coaching/training, financial support and networking activities.
I have an idea for a new business.
What should I do next?
Get coaching!
Read more »I need to improve my business skills.
What are my options?
Get training!
Read more »I have a (draft) business plan.
How do I get my business started?
Get financing!
Read more »I have just started a company.
Where can I get answers to day-to-day issues?
Get connected!
Read more »
Latest News
- 10 May 2012 Dutch vaccine development company Mucosis B.V. announced Phase I clinical data providing proof-of-concept that Mimopath® -based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract. Read more »
- 14 March 2012 FlexGen launched the gene searcher tool on their website. The free tool allows researchers and clinicians to search for pre-defined FleXelect kits that target their genes of interest for next generation sequencing. Read more »
- 27 February 2012 Sleep Position Trainer of NightBalance helps apnea patients of their extreme tiredness. The Sleep Position Trainer is an innovative device aimed at treating sleep apnea, a disease with a high unmet medical need that poses a significant societal burden. Read more »
- 24 February 2012 On 17 February 2012, More than 60 BioBusiness Entrepreneurs came together at the Bioscience Park Leiden to discuss financial possibilities for their businesses. Read more »
- 26 January 2012 Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced that it has raised €23 million in new equity financing. Read more »
